Year: 2025 | Month: July | Volume: 12 | Issue: 7 | Pages: 508-516
DOI: https://doi.org/10.52403/ijrr.20250752
Transforming Chronic Hepatitis C Treatment with Innovation, Efficacy and Challenges
Tadikonda Rama Rao1, Sunkoju Vanisri2
1Professor and Principal, CMR College of Pharmacy, Hyderabad, Telangana, India
2Department of Pharmaceutical Analysis, CMR College of Pharmacy, Hyderabad, Telangana, India
Corresponding Author: Tadikonda Rama Rao
ABSTRACT
One of the main causes of liver disorders, such as Cirrhosis and Hepatocellular Carcinoma, is the hepatitis C virus (HCV). Roughly 3% of people worldwide have HCV infection. HCV infection is therefore seen as a public health concern. It is important to note that the prevalence of HCV varies by country, with high endemic countries having infection rates of about 20%. An estimated 170 million individuals have a chronic HCV infection. In many nations, end-stage liver disease linked to HCV is the primary reason for liver transplantation. The tendency of HCV infection to be chronic is one of its characteristics. Due to the large degree of genetic diversity, HCV can evade the host's immunological response. Liver lesions are mostly associated with immune-mediated mechanisms, which are typified by a preponderance of type 1 helper cell response, and HCV is not directly cytopathic. Although little is known about the co-factors that affect the disease's outcome, such as age, gender, and alcohol use, other factors, like immunologic and genetic factors, might be crucial. Thus, the term "silent disease" refers to hepatitis C. During infection, neutralizing antibodies are generated against a number of HCV proteins; yet, the virus mutates to evade these antibodies. Fatigue, muscle pains, nausea, and discomfort are some of the symptoms that some individuals with chronic hepatitis C may experience. Chronic HCV infection has also been linked to immune-complex-mediated and autoimmune disorders.
Keywords: Hepatitis C virus, Liver disorders, Cirrhosis, Hepatocellular carcinoma
[PDF Full Text]